

Virginia G Kaklamani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3982403/publications.pdf>

Version: 2024-02-01

44
papers

3,667
citations

279798

23
h-index

330143

37
g-index

48
all docs

48
docs citations

48
times ranked

5656
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 111-121.	27.0	1,558
2	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2395-2405.	27.0	349
3	Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. <i>Cancer Cell</i> , 2021, 39, 1091-1098.e2.	16.8	199
4	Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 3246-3256.	1.6	190
5	The role of the fat mass and obesity associated gene (FTO) in breast cancer risk. <i>BMC Medical Genetics</i> , 2011, 12, 52.	2.1	132
6	Variants of the Adiponectin (<i>ADIPOQ</i>) and Adiponectin Receptor 1 (<i>ADIPOR1</i>) Genes and Colorectal Cancer Risk. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 1523.	7.4	127
7	Variants of the Adiponectin and Adiponectin Receptor 1 Genes and Breast Cancer Risk. <i>Cancer Research</i> , 2008, 68, 3178-3184.	0.9	104
8	Combined Genetic Assessment of Transforming Growth Factor- β Signaling Pathway Variants May Predict Breast Cancer Risk. <i>Cancer Research</i> , 2005, 65, 3454-3461.	0.9	83
9	Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ER \pm -GREB1 Transcriptional Axis. <i>Cancer Research</i> , 2018, 78, 671-684.	0.9	80
10	Metabolic Syndrome and Triple-Negative Breast Cancer: A New Paradigm. <i>International Journal of Breast Cancer</i> , 2012, 2012, 1-10.	1.2	79
11	Epirubicin Versus Doxorubicin: Which Is the Anthracycline of Choice for the Treatment of Breast Cancer?. <i>Clinical Breast Cancer</i> , 2003, 4, S26-S33.	2.4	76
12	Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degradar, in ER-Positive, HER2-Negative Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1360-1370.	1.6	69
13	Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study. <i>Clinical Cancer Research</i> , 2021, 27, 3061-3068.	7.0	66
14	Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579). <i>Breast Cancer Research and Treatment</i> , 2015, 151, 629-638.	2.5	61
15	Yttrium-90 Radioembolization Stops Progression of Targeted Breast Cancer Liver Metastases after Failed Chemotherapy. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 1523-1532.e2.	0.5	55
16	Polymorphisms of <i>ADIPOQ</i> and <i>ADIPOR1</i> and prostate cancer risk. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 1234-1243.	3.4	51
17	Role of TGF- β in cancer and the potential for therapy and prevention. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 649-661.	2.4	47
18	EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer. <i>Future Oncology</i> , 2019, 15, 3209-3218.	2.4	43

#	ARTICLE	IF	CITATIONS
19	New targeted therapies in breast cancer. <i>Seminars in Oncology</i> , 2004, 31, 20-25.	2.2	37
20	Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 833-842.	2.5	30
21	Adiponectin pathway polymorphisms and risk of breast cancer in African Americans and Hispanics in the Women's Health Initiative. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 461-468.	2.5	27
22	A Coalitional Cannabis Survey Study of breast cancer patients' use of cannabis before, during, and after treatment. <i>Cancer</i> , 2022, 128, 160-168.	4.1	27
23	Role of capecitabine (Xeloda®) in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 137-144.	2.4	23
24	Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 2704-2710.	7.0	21
25	The Effect of Smoking on the Clinical Features of Adamantiades-Behçet's Disease. , 2003, 528, 323-327.		20
26	Everolimus Inhibits the Progression of Ductal Carcinoma <i>In Situ</i> to Invasive Breast Cancer Via Downregulation of MMP9 Expression. <i>Clinical Cancer Research</i> , 2020, 26, 1486-1496.	7.0	16
27	No major association between TGFBR1*6A and prostate cancer. <i>BMC Genetics</i> , 2004, 5, 28.	2.7	14
28	Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer. <i>Future Oncology</i> , 2019, 15, 1641-1653.	2.4	14
29	Subtype-Guided 18F-FDG PET/CT in Tailoring Axillary Surgery Among Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: A Feasibility Study. <i>Oncologist</i> , 2020, 25, e626-e633.	3.7	12
30	Transforming Growth Factor Beta and Breast Cancer. , 2005, 126, 129-156.		10
31	Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer. <i>Oncologist</i> , 2016, 21, 922-930.	3.7	10
32	Evaluating the Effect of a Video Education Curriculum for First Time Breast Cancer Patients: a Prospective RCT Feasibility Study. <i>Journal of Cancer Education</i> , 2019, 34, 1234-1240.	1.3	9
33	ER±-related chromothripsis enhances concordant gene transcription on chromosome 17q11.1-q24.1 in luminal breast cancer. <i>BMC Medical Genomics</i> , 2020, 13, 69.	1.5	6
34	BRCA 1/2 gene mutation and gastrointestinal stromal tumours: a potential association. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014208830.	0.5	6
35	Role of Polymorphisms in Adamantiades-Behçet's Disease. <i>Journal of Rheumatology</i> , 2008, 35, 2376-2378.	2.0	5
36	Global experience with ixabepilone in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 683-692.	2.4	3

#	ARTICLE	IF	CITATIONS
37	Disparities in Cancer Genetic Testing and Variants of Uncertain Significance in the Hispanic Population of South Texas. JCO Oncology Practice, 2022, 18, e805-e813.	2.9	3
38	Can novel genetic polymorphisms predict response to therapy in acute myeloid leukemia?. Leukemia and Lymphoma, 2010, 51, 1161-1162.	1.3	1
39	Breast Cancer Prevention. American Journal of Cancer, 2002, 1, 173-178.	0.4	0
40	Capecitabine: treatment options in metastatic breast cancer. Expert Review of Obstetrics and Gynecology, 2009, 4, 367-376.	0.4	0
41	Toxicity disparities between Hispanics and non-Hispanics enrolled in clinical trials in south Texas.. Journal of Clinical Oncology, 2017, 35, e18089-e18089.	1.6	0
42	Advances in adjuvant chemotherapy for breast cancer: the role of taxanes. Journal of the National Comprehensive Cancer Network: JNCCN, 2003, 1 Suppl 1, S107-18.	4.9	0
43	Reply to the siren's song of anonymous web-based sampling. Cancer, 2022, 128, 1873-1874.	4.1	0
44	Anti-estrogen Therapy and Fertility Preservation in Premenopausal Breast Cancer Patients: a Review. Current Breast Cancer Reports, 0, , 1.	1.0	0